TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02076191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered at doses of 5mg, 10mg, 15mg, or 25 mg taken orally every 12 hours throughout the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is administered intravenously at a dose of 20 mg/m2 daily for 5 days. Subsequent cycles of decitabine may be administered at 4 week intervals as clinically tolerated. Decitabine treatment may be deferred for up to 2 weeks to allow recovery from non-hematologic toxicity during the first 6 cycles and up to 2 weeks thereafter for hematologic toxicities as well. The first treatment cycle will last 35 days and will be the evaluable period for DLTs and RPTD determination for patients enrolled in the phase I portion only. Subsequent treatment cycles will be 4-6 weeks in duration as defined by decitabine administration.
Study: NCT03006250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane is the volatile agent with low blood: gas partition coefficient (0.42), its uptake and elimination from the body of a patient are rapid, which results in a fast onset of anesthesia and a fast recovery from anesthesia. This property provides desflurane as an ideal agent for the ambulatory anesthesia. However, its pungent odor is concerned to irritate the upper airway and may cause significant respiratory complications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane has a blood: gas partition coefficient of 0.65, which is slightly greater than desflurane. The major advantage over desflurane is the better scented. It is considered to be less airway irritation in LMA anesthesia with smooth induction and recovery.
Study: NCT01311492

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Lifestyle Program
Description: The healthy lifestyle program includes upper body stretching and educational workshops. The purpose of this group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest. The rational for this placebo exercise activity is that it helps foster adherence to this arm of the study and increases the perceived benefit of the healthy lifestyle program to the participants without directly affecting the study outcomes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Intervention
Description: The physical activity intervention consists of a general weekly physical activity goal of 150 minutes. This is consistent with the public health message from the Surgeon General's report that moderate physical activity should be performed for 30 minutes on most if not all days of the week (150-210 total minutes). This goal is approached in a progressive manner over the course of the trial.
Study: NCT01571362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-02
Description: 20 to 160mg total daily dose of oxycodone, divided into symmetric doses and administered twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo, divided into symmetric doses and administered twice daily
Study: NCT02529774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)
Description: Hepatic Artery Infusion for four cycles:~Floxuridine (FUDR) 500mg/d, Day 1-2; DXM 1mg/day added to FUDR 2-day infusion; Heparin 1000U/day added to FUDR 2-day infusion~In combination with Systemic Chemotherapy CapeOX for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or in combination with Systemic Chemotherapy mFOLFOX6 for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1
Study: NCT02414425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectoscopy
Description: A rectoscopy will be performed for Botulinum toxin A or physiologic serum injection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rectoscopy
Description: A rectoscopy will be performed for Botulinum toxin A or physiologic serum injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anorectal manometry
Description: Anorectal manometry will be performed to evaluate efficacy of Botulinum toxin A or physiologic serum rectal injection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Anorectal manometry
Description: Anorectal manometry will be performed to evaluate efficacy of Botulinum toxin A or physiologic serum rectal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A or physiologic serum injection
Description: Botulinum toxin A or physiologic serum injection is performed during rectoscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum toxin A or physiologic serum injection
Description: Botulinum toxin A or physiologic serum injection is performed during rectoscopy
Study: NCT03392376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol Injection
Description: ICU patients with diagnosed delirium are treated with 2,5mg haloperidol x 3 daily intravenously with additional as needed doses to a maximum of 20mg/daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (0,9%)
Description: ICU patients with diagnosed delirium are treated with 0,5ml isotonic saline x 3 daily and as needed doses to a maximum of 4ml/daily, corresponding to the algorithm in the experimental arm.
Study: NCT03862625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a modular adaptive seating system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercise program for scoliosis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home exercise program for scoliosis
Study: NCT02685956

Intervention type: DEVICE
Intervention: Vela Sentosa SA HSV1/2 Qualitative PCR Test
Description: medical device test using Vela Sentosa SA HSV1/2 Qualitative PCR Test
Study: NCT06182007

Intervention type: PROCEDURE
Intervention: Cardiopulmonary Resuscitation
Description: Cardiopulmonary Resuscitation (Advanced Life Support) according to current guidelines

Intervention type: PROCEDURE
Intervention: Cardiopulmonary Resuscitation
Description: Cardiopulmonary Resuscitation (Advanced Life Support) according to current guidelines
Study: NCT00642564

Intervention type: OTHER
Intervention: Observational study in Epileptic Patients
Description: Observation study in Epileptic Patients with Migraine and Headache
Study: NCT03489668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: metformin administration 1500mg per day
Study: NCT03775148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
Description: TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
Study: NCT01860482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Newrabell® Tablet 10mg
Study: NCT02691806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental protocol
Description: first day- VO2max test with the following measurements: anaerobic threshold, maximum oxygen consumption, heart rate and breathing indices.~second day- performing the same physical protocol of VO2max test with the measurements: leg muscles activity using a wireless EMG, hemodynamic measurements of oxygen levels in the skin and skin perfusion, the two latest using optic sensors.
Study: NCT01321112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conversion from CNI to MMF
Description: After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
Study: NCT01015612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve® System
Description: The Medtronic CoreValve® System device is designed to replace the native aortic valve without the requirement for open heart surgery and without concomitant surgical removal of the failed native valve in patients with symptomatic severe aortic stenosis who have an elevated surgical risk
Study: NCT01047059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib, Bevacizumab
Description: Erlotinib 150mg/d d1-d43 p.o. Bevacizumab 15mg/kg b. w. d1, d22, d43 i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoro-D-glucose
Description: Tracer for PET imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoro-L-thymidine
Description: FLT-PET tracer for imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium-DPTA
Description: Contrast agent for DCE-MRI imaging
Study: NCT03529513

Intervention type: DIAGNOSTIC_TEST
Intervention: Medibio Depression Diagnostic Aid
Description: The Medibio DDA processes the heart rate and actigraphy data from the third-party devices, characterizes these data in comparison to the benchmark patterns of persons currently experiencing a depressive episode.
Study: NCT02529774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)
Description: Systemic Chemotherapy CapeOX alone for 8 cycles:~Oxaliplatin 130 mg/m\^2 iv over 2 hours, Day 1. Capecitabine 850mg/m\^2/d PO Bid, given in the morning and evening, Day 1-14~Or Systemic Chemotherapy mFOLFOX6 alone for 12 cycles:~Oxaliplatin 85mg/m\^2 IV over 2 hours, Day 1. Leucovorin 400mg/m\^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m\^2 IV and then 2400mg/m\^2 over 48 hours IV continuous infusion. Day 1
Study: NCT00924885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swemed Follicle Aspiration Set Reduced Single Lumen
Description: Thin tip to penetrate the tissue

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Swemed Follicle Aspiration Set Single Lumen (1.4 mm)
Description: Standard (1.4 mm) needle to penetrate the tissue
Study: NCT01348451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgical implantation
Description: human spinal cord stem cell implantation in ALS patients
Study: NCT02161744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADSCs administration
Description: 100- 240 cc of lipoaspirate will be extracted from the patient. The stromal vascular fraction (SVF) will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient.
Study: NCT03507166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2 mg/kg IV every 2 weeks
Study: NCT02777151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3470-3471-3479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3470-3471-3479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3470-3471-3479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN3470-3471-3479
Study: NCT03433118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture administered by specially-trained therapeutic radiographers
Study: NCT00410852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer-assisted IV insulin infusion protocol (algorithm A)
Description: Computer assisted insulin protocol (CAIP), with continuous intravenous insulin adjustments aiming blood glucose levels between 100 mg/dl and 130 mg/dl.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leuven Strict glycemic control protocol (Algorithm B)
Description: Leuven protocol: continuous intravenous insulin infusion aimiming blood glucose levels between 80mg/dl and 110mg/dl.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Intermittent Insulin Protocol (Algorithm C)
Description: Conventional treatment: intermitent subcutaneous insulin according to a sliding scale, starting with blood glucose levels higher than 150mg/dl.
Study: NCT00945152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)
Description: Topical use for open wounds culturing out MRSA. One to three applications of the compound over a weeks time. Consists of Vancomycin 1.25-1.50% in a complex gel formulation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, complex gel formulation without Vancomycin
Description: Complex gel formulation applied as the placebo and is unknown because of the trial design. Complex gel formulation without Vancomycin
Study: NCT01838161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Part II
Description: Parents will be exposed to an educational video intervention if they are enrolled in this intervention condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Part III
Description: •video educational

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Part I
Description: Parental Interviews
Study: NCT02117479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets to be administered by mouth twice daily (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 5 mg tablets to be administered by mouth twice daily (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 150 and 500 mg tablets to be administered by mouth twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 150 and 500 mg tablets to be administered by mouth twice daily (BID)
Study: NCT02348619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZP-110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZP-110
Study: NCT02818478

Intervention type: OTHER
Group type: OTHER
Intervention: Reporting of patient reported outcome measures
Description: Electronic reporting of patient reported outcome measures from home, compared to reporting of patient reported outcome measures at the outpatient clinic

Intervention type: OTHER
Group type: OTHER
Intervention: Reporting of patient reported outcome measures
Description: Electronic reporting of patient reported outcome measures from home, compared to reporting of patient reported outcome measures at the outpatient clinic

Intervention type: OTHER
Group type: OTHER
Intervention: Reporting of patient reported outcome measures
Description: Electronic reporting of patient reported outcome measures from home, compared to reporting of patient reported outcome measures at the outpatient clinic

Intervention type: OTHER
Group type: OTHER
Intervention: Reporting of patient reported outcome measures
Description: Electronic reporting of patient reported outcome measures from home, compared to reporting of patient reported outcome measures at the outpatient clinic
Study: NCT03990389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chatbot Intervention
Description: a chatbot will be used to monitor depression severity
Study: NCT02667496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim GZ402664
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetapir F18
Description: Pharmaceutical form:solution Route of administration: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Florbetapir F18
Description: Pharmaceutical form:solution Route of administration: intravenous
Study: NCT03330028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg by vein approximately 60 minutes before Paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 50 mg by vein approximately 60 minutes before Paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: 20 mg by vein approximately 60 minutes before Paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Mitomycin C 30 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 200 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Starting dose of Paclitaxel is 20 mg/m2 in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.~Dose-escalation scheme of Paclitaxel is in increments of 5 mg/m2.
Study: NCT03465228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training and LED group
Description: The LED application will be performed before GTL training sessions and will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training group
Description: The training sessions will be monitored based on the subjective perception of exertion of the session (PSESession) (FOSTER, 1998), and heart rate. There will be two types of training: continuous and interval training. The sessions of the training group (GT) and group training + LED (GL) will be preceded by a warm-up of 15 minutes. Participants in the two training groups will undergo weekly training twice weekly on non-consecutive days during four weeks. Continuous training will be 30 minutes at 70% to 80% of maximum heart rate, and interval training will be performed 30 minutes at 100% maximum heart rate of laced racing with fixation of an elastic tube in the floating vest, 30 seconds of intense running and 30 seconds interval. The LED off will be performed before training sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training group
Description: The training sessions will be monitored based on the subjective perception of exertion of the session (PSESession) (FOSTER, 1998), and heart rate. There will be two types of training: continuous and interval training. The sessions of the training group (GT) and group training + LED (GL) will be preceded by a warm-up of 15 minutes. Participants in the two training groups will undergo weekly training twice weekly on non-consecutive days during four weeks. Continuous training will be 30 minutes at 70% to 80% of maximum heart rate, and interval training will be performed 30 minutes at 100% maximum heart rate of laced racing with fixation of an elastic tube in the floating vest, 30 seconds of intense running and 30 seconds interval. The LED off will be performed before training sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LED group
Description: This group will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
Study: NCT02232451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERCP with loop tip wire
Description: Endoscopic retrograde cholangio-pancreatography with guide wire (loop-tip) for CBD cannulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP for cannulation
Description: Endoscopic retrograde cholangio-pancreatography with traditional technique for CBD cannulation
Study: NCT03582371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stand-Up Paddle Rehabilitation
Description: Patients in the Aqua SUP group will benefit from a 1 hour Aqua SUP session, twice a week, for 8 weeks in a therapeutic pool.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy Rehabilitation
Description: Patients in the control group will receive a conventional physiotherapy session of 1 hour, twice a week, for 8 weeks.
Study: NCT00767689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B 6
Description: vitamin b6 100 mg po daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo is given in the placebo arm
Study: NCT02367079

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Diathermy
Description: Sham diathermy vs switched on diathermy effect on pain where assessed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diathermy
Description: Sham diathermy vs switched on diathermy effect on pain where assessed
Study: NCT00654043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torsemide
Description: tablets, 20 Mg, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Demadex
Description: Tablets, 20 mg, single-dose
Study: NCT02292433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 high dose
Description: tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days
Study: NCT02777151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00990223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone or Placebo
Description: Eplerenone 100 mg or Placebo, daily for 10 days.
Study: NCT01060761

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program
Description: Patient and their relative receive three supportive, structured conversation with a trained nurse.~Patient and their relative receive 4 days Retreat Weekend with supportive talk and activities
Study: NCT01090804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreatheMAX breathing device
Description: secretion clearance, breathing exercise
Study: NCT04399629

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PCIT-ED
Description: 12 sessions of PCIT-ED therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Wisely
Description: Teaches parents how to set more effective limits